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Opioid medications are an underappreciated cause of serotonin syndrome.  Fentanyl, meperidine, 
and methadone are more commonly associated with this potentially life-threatening side effect.  
Here, we present the case of a 60-year-old man taking duloxetine, oxycodone as needed, and 
long-acting hydromorphone for chronic pain, who developed serotonin syndrome two days after 
his hydromorphone dose was increased.  Due to severe agitation he required intubation and his 
course was notable for marked adrenergic instability. Eventually, he improved after treatment 
with benzodiazepines and cyproheptadine.  This case highlights a rare synergistic effect from the 
combination of hydromorphone, duloxetine, and oxycodone resulting in serotonin syndrome. 
 
 
OBJECTIVE:  
 
To alert clinicians about the risk of 
hydromorphone precipitating serotonin 
syndrome when given in conjunction with 
other serotonergic agents. 
 
BACKGROUND: 
 
Chronic pain is a challenging disorder to 
treat and is frequently associated with 
depression and anxiety.  Opioids are often 
combined with serotonergic agents, where 
the serotonergic drugs may be used to treat 
concomitant psychiatric illness, or directly 
to treat pain itself.  However, there remains 
a great deal of uncertainty regarding optimal 
drug combinations and potentiation of side 
effects.
1
   
Serotonin syndrome is a severe 
adverse reaction, which is typically 
associated with serotonergic drugs, such as 
selective serotonin reuptake inhibitors  
 
(SSRIs), serotonin-norepinephrine reuptake 
inhibitors (SNRIs), tricyclics, as well as 
illicit substances, such as ecstasy (MDMA) 
or amphetamines.  However, there are a 
huge number of other drugs that act upon the 
serotonergic system in unpredictable ways, 
which may not always be apparent to the 
prescriber.  The syndrome is characterized 
by a triad of mental status changes, 
autonomic hyperactivity, and neuromuscular 
abnormalities, but not all three need to be 
present to make the diagnosis.
2
 
Most clinicians would probably not 
consider opioids to play a major role in 
serotonin syndrome, although certainly 
some specific agents, such as meperidine, 
have become well-known for this effect, as 
seen with the unfortunate case of Libby 
Zion.  Nevertheless, the FDA has started to 
warn that all opioids may have this effect.
3
 
This case report describes a patient who was 
taking a regimen for chronic pain with SNRI 
and opioids, and unfortunately developed 
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severe serotonin syndrome after his 
hydromorphone dose was increased.  
 
CASE PRESENTATION: 
 
A 60-year-old male presented to the 
Emergency Department (ED) due to anxiety.  
He had a history of coronary artery disease, 
paroxysmal atrial fibrillation, chronic 
obstructive pulmonary disease, spinal 
stenosis status post L3-L5 decompressive 
surgery, and residual back pain treated with 
chronic oral narcotics.  His medication list is 
shown in Table 1.  He had been noted by his 
primary care physician to be highly 
compliant with medications and was on a 
chronic narcotic contract. 
Two days prior to presentation, the 
patient’s oral hydromorphone dosage had 
been increased from 16 mg to 24 mg/day.  
After this medication change, the patient 
became acutely restless and agitated.  He 
could not sleep at all the previous night.  His 
wife went to work in the morning, and when 
she came that home in the evening she found 
him incredibly frantic, pacing, anxious, and 
unable to sit still. 
 In the ED his vitals were noted to be 
highly labile.  His systolic blood pressures 
ranged from 93 to 183 mmHg and diastolic 
pressures ranged from 52 to 110 mmHg.  He 
was afebrile.  His heart rate ranged from 100 
to 140 beats per minute.  His respiratory rate 
was 20 breaths per minute.  He appeared 
diaphoretic, could not lay still in the bed, 
and was noted to be pacing restlessly.  
Cardiopulmonary examination was 
unremarkable except for tachycardia.  On 
neurologic exam, he was noted to have 
hyperreflexia throughout, inducible 
sustained myoclonus in the lower 
extremities bilaterally, and bilateral upgoing 
toes.  No overt muscle rigidity was noted. 
 He was given several doses of 
intravenous lorazepam (6 mg total), but 
became increasingly combative. He was 
finally intubated due to his altered mental 
status and concern for airway compromise. 
His initial laboratory values, 
including complete blood count, 
electrolytes, thyroid stimulating hormone, 
hepatic function tests, and urine drug screen 
were unremarkable.  His lumbar puncture 
and computed tomography scan of the head 
were also unremarkable. 
 
Table 1. Patient’s medication list. All routes are oral unless specified. 
 
Aspirin 81 mg daily 
Albuterol metered dose inhaler, 90 mcg/actuation, 2 puffs inhaled every 4-6 hours as needed for 
wheezing 
Baclofen 10 mg three times daily 
Duloxetine 60 mg twice daily 
Docusate 100 mg as needed for constipation 
Fluticasone-salmeterol 100/50 mcg 1 puff inhaled twice daily 
Furosemide 20 mg daily 
Hydromorphone sustained-release 24 mg daily 
Lisinopril 20 mg daily 
Metoprolol succinate 100 mg daily 
Oxycodone 5 mg daily as needed for breakthrough pain 
Rosuvastatin 40 mg daily 
Sildenafil 50 mg as needed for erectile dysfunction 
Spironolactone 12.5 mg daily 
Warfarin (dose varies) 
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The patient’s presentation was felt to 
be consistent with serotonin syndrome 
precipitated by the hydromorphone dose 
increase and fulfilled the Hunter criteria (see 
discussion).  He was sedated with 
midazolam and dexmedetomidine, and 
cyproheptadine was started at a loading dose 
of 12 mg, followed by 4 mg every 6 hours.  
He was extubated on hospital day #3, but 
remained delirious for several days 
thereafter.  Over the next few days he also 
developed mild rhabdomyolysis and had 
intermittent fevers as high as 38.3°C with 
negative infectious workup. 
 He was eventually discharged from 
the hospital and has since tapered off 
duloxetine and hydromorphone completely.  
He remains on a small dose of oxycodone 
and has been started on gabapentin and 
medical cannabis. 
 
DISCUSSION 
 
The neurotransmitter 5-hydroxytryptamine, 
otherwise known as serotonin, is synthesized 
from the amino acid tryptophan.  Its 
regulation, metabolism, and reuptake 
mechanisms are complex and will not be 
discussed in detail here.  However, it is 
important to recall that the enzyme 
monoamine oxidase breaks down serotonin; 
hence, MAO inhibitors such as phenelzine 
can precipitate serotonin syndrome.   Drugs 
which cause massive release of serotonin 
(such as ecstasy), inhibition of reuptake 
(such as SSRIs), or direct receptor agonism 
(such as fentanyl and buspirone) can cause 
serotonin syndrome.  It is also important to 
recognize that hepatic cytochrome P450 
enzyme inhibitors can increase drug levels.
2
 
For example, in one case, a child taking a 
stable dose of sertraline suffered serotonin 
syndrome after being exposed to 
erythromycin.
4
 
Serotonin syndrome is a potentially life-
threatening side effect of serotonergic drugs.  
It can be diagnosed via the Hunter Criteria, 
which stipulates that the patient must be on a 
serotonergic agent and meet one of the 
following conditions
5
: 
 Spontaneous clonus 
 Inducible clonus PLUS agitation or 
diaphoresis 
 Ocular clonus PLUS agitation or 
diaphoresis 
 Tremor PLUS hyperreflexia 
 Hypertonia PLUS temperature above 
38°C PLUS ocular clonus or 
inducible clonus 
 
Symptoms present relatively quickly 
after a medication is started or a dose is 
increased – typically within 24-48 hours.  
These symptoms occur along a spectrum of 
severity, which makes both initial diagnosis 
and prevention of progression challenging.  
Patients may experience some mild diarrhea 
or tremor which many clinicians may not 
associate with serotonin syndrome.  Many 
patients may not report some of these 
symptoms to their physicians at all.  More 
severe cases can cause autonomic instability, 
diaphoresis, mydriasis, hyperreflexia, 
clonus, or severe agitation as seen in this 
case.  Interestingly, after his recovery, this 
patient recalled that he felt “like a kettle 
ready to boil” in the days leading up to the 
hydromorphone dose increase which 
ultimately precipitated the full-blown 
syndrome.  He did not mention this to his 
physician, and it is very possible that even if 
he had, his vague complaint may not have 
been attributed to serotonin syndrome.  
After all, he was on a stable dose of 
duloxetine, and hydromorphone is not 
typically associated with the syndrome.  
There is an increasing evidence that 
all opioids can precipitate serotonin 
syndrome, although the mechanisms are 
likely hetereogeneous.
3,6
 This patient’s 
reaction represents a dose-related adverse 
drug reaction caused by hydromorphone 
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dose increase in setting of stable chronic 
doses of duloxetine and oxycodone.  
Chronic pain is frequently treated with a 
combination of antidepressants and opioids.
7
 
When prescribing this combination, 
clinicians must be aware of this potentially 
severe interaction. 
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